

## DAFTAR PUSTAKA

- Akdis, M., Aab, A., Altunbulakli, C., et al., 2016. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor  $\beta$ , and TNF- $\alpha$ : Receptors, functions, and roles in diseases, *Journal of Allergy and Clinical Immunology* Mosby138 (4):984–1010.
- Akulian, J., Yarmus, L. and Feller-Kopman, D., 2013. The Evaluation and Clinical Application of Pleural Physiology, *Clinics in Chest Medicine* Elsevier34 (1):11–19.
- Al-Lamki, R.S., Bradley, J.R. and Pober, J.S., 2017. Human Organ Culture: Updating the Approach to Bridge the Gap from In Vitro to In Vivo in Inflammation, Cancer, and Stem Cell Biology., *Frontiers in Medicine* Switzerland4148.
- Assoian, R.K., Fleurdeleys, B.E., Stevenson, H.C., et al., 1987. Expression and secretion of type beta transforming growth factor by activated human macrophages., *Proceedings of the National Academy of Sciences of the United States of America* United States84 (17):6020–6024.
- Awad, M.R., El-Gamel, A., Hasleton, P., Turner, D.M., Sinnott, P.J. and Hutchinson, I. V, 1998. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation., *Transplantation* United States66 (8):1014–1020.
- Batra, H. and Antony, V.B., 2015. Pleural mesothelial cells in pleural and lung diseases., *Journal of Thoracic Disease* 7 (6):964–980.
- Bobbio, A., Bouam, S., Frenkel, J., et al., 2021. Epidemiology and prognostic factors of pleural empyema, *Thorax* BMJ Publishing Group Ltd76 (11):1117–1123.
- Bostock, I.C., Sheikh, F., Millington, T.M., Finley, D.J. and Phillips, J.D., 2018. Contemporary outcomes of surgical management of complex thoracic infections., *Journal of Thoracic Disease* 10 (9):5421–5427.
- Bradshaw, M., Mansfield, A. and Peikert, T., 2013. The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion, *Current Oncology Reports* 2013 15:3 Springer15 (3):207–216.
- Broaddus, V.C. and Light, R.W., 2016. Pleural effusion, *Murray and Nadel's Textbook of Respiratory Medicine* Elsevierpp. 1396–1424.
- Chen, B., Huang, S., Su, Y., et al., 2019. Macrophage Smad3 Protects the Infarcted Heart, Stimulating Phagocytosis and Regulating Inflammation, *Circulation Research* Circ Res125 (1):55–70.
- Chen, L.-J., Ye, H., Zhang, Q., et al., 2015. Bleomycin induced epithelial-

- mesenchymal transition (EMT) in pleural mesothelial cells., *Toxicology and Applied Pharmacology* United States283 (2):75–82.
- Chen, W. and Ten Dijke, P., 2016. Immunoregulation by members of the TGF $\beta$  superfamily., *Nature Reviews. Immunology* England16 (12):723–740.
- Cheng, Y.F., Cheng, C.Y., Huang, C.L., Hung, W.H. and Wang, B.Y., 2022. Pleural Peels Tissue Culture plus Pleural Fluid Culture Help to Improve Culture Rate for Empyema, *Journal of Clinical Medicine* 11 (7):, available at:<https://doi.org/10.3390/jcm11071882>.
- Chou, C.-H., Cheng, Y.-F., Siow, T.Y., Kumar, A., Peck, K. and Chang, C., 2013. SCUBE3 regulation of early lung cancer angiogenesis and metastatic progression., *Clinical & Experimental Metastasis* Netherlands30 (6):741–752.
- Corcoran, J.P., Wrightson, J.M., Belcher, E., DeCamp, M.M., Feller-Kopman, D. and Rahman, N.M., 2015. Pleural infection: past, present, and future directions., *The Lancet. Respiratory Medicine* England3 (7):563–577.
- Cui, H. and Liu, G., 2022. DOCK-t(w)o Pleural Fibrosis, *American Journal of Respiratory Cell and Molecular Biology* 66 (2):117–119.
- DeBiasi, E.M. and Feller-Kopman, D., 2021. Anatomy and Applied Physiology of the Pleural Space, *Clinics in Chest Medicine* 42 (4):567–576.
- Fedchenko, N. and Reifenrath, J., 2014. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review, *Diagnostic Pathology* 9221.
- Feller-Kopman, D. and Light, R., 2018. Pleural Disease., *The New England Journal of Medicine* United States378 (8):740–751.
- Fiorelli, A., Ricci, S., Feola, A., et al., 2016. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in diagnosis of pleural effusion of malignant origin, *Interactive CardioVascular and Thoracic Surgery* Oxford Academic22 (4):411–418.
- Frangogiannis, N.G., 2020. Transforming growth factor- $\beta$  in tissue fibrosis, *The Journal of Experimental Medicine* The Rockefeller University Press217 (3):, available at:<https://doi.org/10.1084/JEM.20190103>.
- Garbisa, S., Sartor, L., Biggin, S., Salvato, B., Benelli, R. and Albini, A., 2001. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate., *Cancer* United States91 (4):822–832.
- Gerwin, B.I., Lechner, J.F., Reddel, R.R., et al., 1987. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines., *Cancer Research* United States47 (23):6180–6184.
- Gilmer, J., Harding, T., Woods, L., Black, B., Flores, R. and Pfau, J., 2017. Mesothelial cell autoantibodies upregulate transcription factors associated

- with fibrosis, *Inhalation Toxicology* Taylor & Francis29 (1):10–17.
- Hasan, H. and Ambarwati, D., 2019. Empiema, *Jurnal Respirasi* 4 (1):26.
- Hinz, B., McCulloch, C.A. and Coelho, N.M., 2019. Mechanical regulation of myofibroblast phenoconversion and collagen contraction, *Experimental Cell Research* Exp Cell Res379 (1):119–128.
- Hossen, I., Kaiqi, Z., Hua, W., Junsong, X., Mingquan, H. and Yanping, C., 2023. Epigallocatechin gallate (EGCG) inhibits lipopolysaccharide-induced inflammation in RAW 264.7 macrophage cells via modulating nuclear factor kappa-light-chain enhancer of activated B cells (NF- $\kappa$ B) signaling pathway, *Food Science and Nutrition* 11 (8):4634–4650.
- Huo, Q., He, X., Li, Z., et al., 2021. SCUBE3 serves as an independent poor prognostic factor in breast cancer., *Cancer Cell International* 21 (1):268.
- Jantz, M.A. and Antony, V.B., 2008. Pathophysiology of the Pleura, *Respiration* Karger Publishers75 (2):121–133.
- Kaarteenaho-Wiik, R., Lakari, E., Soini, Y., Pöllänen, R., Kinnula, V.L. and Pääkkö, P., 2000. Tenascin expression and distribution in pleural inflammatory and fibrotic diseases., *The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society United States*48 (9):1257–1268.
- Kaczmarek, M. and Sikora, J., 2012. Macrophages in malignant pleural effusions – alternatively activated tumor associated macrophages, *Contemporary Oncology/Współczesna Onkologia* Termedia16 (4):279–284.
- Khalil, H., Kanisicak, O., Prasad, V., et al., 2017. Fibroblast-specific TGF- $\beta$ -Smad2/3 signaling underlies cardiac fibrosis., *The Journal of Clinical Investigation* 127 (10):3770–3783.
- Kunz, C.R., Jadus, M.R., Kukes, G.D., Kramer, F., Nguyen, V.N. and Sasse, S.A., 2004. Intrapleural injection of transforming growth factor-beta antibody inhibits pleural fibrosis in empyema., *Chest United States*126 (5):1636–1644.
- Lansley, S.M., Cheah, H.M. and Lee, Y.C.G., 2017. Role of MCP-1 in pleural effusion development in a carrageenan-induced murine model of pleurisy, *Respirology* John Wiley & Sons, Ltd22 (4):758–763.
- Lee, Y.C. and Lane, K.B., 2001. The many faces of transforming growth factor-beta in pleural diseases., *Current Opinion in Pulmonary Medicine United States*7 (4):173–179.
- Liang, W., Yang, C., Peng, J., Qian, Y. and Wang, Z., 2015. The Expression of HSPD1, SCUBE3, CXCL14 and Its Relations with the Prognosis in Osteosarcoma, *Cell Biochemistry and Biophysics* 73 (3):763–768.
- Liao, W.J., Wu, M.Y., Peng, C.C., Tung, Y.C. and Yang, R.B., 2020. Epidermal growth factor-like repeats of SCUBE1 derived from platelets are critical for

- thrombus formation, *Cardiovascular Research* Cardiovasc Res116 (1):193–201.
- Lin, Y.C., Lee, Y.C., Li, L.H., Cheng, C.J. and Yang, R.B., 2014. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition, *Journal of Cell Science* J Cell Sci127 (Pt 1):85–100.
- Madhi, F., Levy, C., Morin, L., et al., 2019. Change in Bacterial Causes of Community-Acquired Parapneumonic Effusion and Pleural Empyema in Children 6 Years After 13-Valent Pneumococcal Conjugate Vaccine Implementation., *Journal of the Pediatric Infectious Diseases Society* England8 (5):474–477.
- Maeda-Yamamoto, M., Kawahara, H., Tahara, N., Tsuji, K., Hara, Y. and Isemura, M., 1999. Effects of tea polyphenols on the invasion and matrix metalloproteinases activities of human fibrosarcoma HT1080 cells., *Journal of Agricultural and Food Chemistry* United States47 (6):2350–2354.
- Mähler, A., Mandel, S., Lorenz, M., et al., 2013. Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?, *EPMA Journal* 4 (1):5.
- Martin, M., Lefaix, J. and Delanian, S., 2000. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target?, *International Journal of Radiation Oncology, Biology, Physics* United States47 (2):277–290.
- McDonald, L.T., Zile, M.R., Zhang, Y., et al., 2018. Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis, *American Journal of Physiology. Heart and Circulatory Physiology* Am J Physiol Heart Circ Physiol315 (1):H92–H100.
- Metelmann, I.B., Kraemer, S., Steinert, M., Langer, S., Stock, P. and Kurow, O., 2022. Novel 3D organotypic co-culture model of pleura., *PloS One* United States17 (12):e0276978.
- Mutsaers, S.E., Birnie, K., Lansley, S., Herrick, S.E., Lim, C.-B. and Prêle, C.M., 2015. Mesothelial cells in tissue repair and fibrosis., *Frontiers in Pharmacology* 6113.
- Nagle, D.G., Ferreira, D. and Zhou, Y.-D., 2006. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives., *Phytochemistry* England67 (17):1849–1855.
- Negrini, D. and Moriondo, A., 2013. Pleural function and lymphatics, *Acta Physiologica* 207 (2):244–259.
- Oikonomidi, S., Kostikas, K., Kalomenidis, I., et al., 2010. Matrix Metalloproteinase Levels in the Differentiation of Parapneumonic Pleural Effusions, *Respiration* Karger Publishers80 (4):285–291.

- Panji, M., Behmard, V., Zare, Z., et al., 2021. Suppressing effects of green tea extract and Epigallocatechin-3-gallate (EGCG) on TGF- $\beta$ - induced Epithelial-to-mesenchymal transition via ROS/Smad signaling in human cervical cancer cells, *Gene* 794145774.
- Pawlak, J.B. and Blobel, G.C., 2022. TGF- $\beta$  superfamily co-receptors in cancer., *Developmental Dynamics : An Official Publication of the American Association of Anatomists United States* 251 (1):137–163.
- Perhimpunan Dokter Paru Indonesia, 2021. *Panduan Umum Praktik Klinik Penyakit Paru Dan Pernafasan*, 1st ed. Perhimpunan Dokter Paru Indonesia, Jakarta.
- Psallidas, I., Kanellakis, N.I., Gerry, S., et al., 2018. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis, *The Lancet Oncology* Elsevier 19 (7):930–939.
- Ranganathan, P., Agrawal, A., Bhushan, R., et al., 2007. Expression profiling of genes regulated by TGF-beta: differential regulation in normal and tumour cells., *BMC Genomics* England 898.
- Ribera, J., Pauta, M., Melgar-Lesmes, P., et al., 2017. A small population of liver endothelial cells undergoes endothelial-to-mesenchymal transition in response to chronic liver injury, *American Journal of Physiology. Gastrointestinal and Liver Physiology* Am J Physiol Gastrointest Liver Physiol 313 (5):G492–G504.
- Rice, L.M., Padilla, C.M., McLaughlin, S.R., et al., 2015. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients, *The Journal of Clinical Investigation J Clin Invest* 125 (7):2795–2807.
- Sasse, S.A., Jadus, M.R. and Kukes, G.D., 2003. Pleural fluid transforming growth factor- $\beta$ 1 correlates with pleural fibrosis in experimental empyema, *American Journal of Respiratory and Critical Care Medicine* 168 (6 I):700–705.
- Schnur, S., Hans, F., Dehne, A., et al., 2023. The Potential of Epigallocatechin-3-gallate (EGCG) as Complementary Medicine for the Treatment of Inflammatory Bowel Disease, *Pharmaceuticals* 16 (5);, available at:<https://doi.org/10.3390/ph16050748>.
- Shen, J., Ma, X., Wei, Z., et al., 2024.  $\beta$ -catenin/TCF4-induced SCUBE3 upregulation promotes ovarian cancer development via HIF-1 signaling pathway, *Molecular and Cellular Endocrinology* 582112127.
- Sicard, A.A., Dao, T., Suarez, N.G. and Annabi, B., 2021. Diet-Derived Gallated Catechins Prevent TGF- $\beta$ -Mediated Epithelial-Mesenchymal Transition, Cell Migration and Vasculogenic Mimicry in Chemosensitive ES-2 Ovarian Cancer Cells, *Nutrition and Cancer Taylor & Francis* 73 (1):169–180.
- da Silva, S.S., Peterson, G.E., Amantéa, S.L., et al., 2018. Transforming growth

- factor beta1 (TGF- $\beta$ 1) levels in a rat model of induced pleural empyema, *Acta Cirurgica Brasileira* 33 (2):156–162.
- Sriram, N., Kalayarasan, S., Manikandan, R., Arumugam, M. and Sudhandiran, G., 2015. Epigallocatechin gallate attenuates fibroblast proliferation and excessive collagen production by effectively intervening TGF- $\beta$ 1 signalling., *Clinical and Experimental Pharmacology & Physiology Australia* 42 (8):849–859.
- Sriram, N., Kalayarasan, S. and Sudhandiran, G., 2009. Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling., *Pulmonary Pharmacology & Therapeutics England* 22 (3):221–236.
- Strange, C., Tomlinson, J.R., Wilson, C., Harley, R., Miller, K.S. and Sahn, S.A., 1989. The histology of experimental pleural injury with tetracycline, empyema, and carrageenan., *Experimental and Molecular Pathology Netherlands* 51 (3):205–219.
- Terrell, T.G., Working, P.K., Chow, C.P. and Green, J.D., 1993. Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits., *International Review of Experimental Pathology United States* 34 Pt B 43–67.
- Tu, C.-F., Tsao, K.-C., Lee, S.-J. and Yang, R.-B., 2014. SCUBE3 (signal peptide-CUB-EGF domain-containing protein 3) modulates fibroblast growth factor signaling during fast muscle development., *The Journal of Biological Chemistry United States* 289 (27):18928–18942.
- Tucker, T.A. and Idell, S., 2022. Update on Novel Targeted Therapy for Pleural Organization and Fibrosis, *International Journal of Molecular Sciences Int J Mol Sci* 23 (3):, available at:<https://doi.org/10.3390/IJMS23031587>.
- Wang, Z., Chen, C., Zhang, J., et al., 2023. Epithelium-derived SCUBE3 promotes polarized odontoblastic differentiation of dental mesenchymal stem cells and pulp regeneration, *Stem Cell Research & Therapy* 14 (1):130.
- Wu, L., Li, C. and Pan, L., 2018. Nasopharyngeal carcinoma: A review of current updates., *Experimental and Therapeutic Medicine* 15 (4):3687–3692.
- Wu, Y.R., Choi, H.J., Kang, Y.G., Kim, J.K. and Shin, J.W., 2017. In vitro study on anti-inflammatory effects of epigallocatechin-3-gallate-loaded nano- and microscale particles, *International Journal of Nanomedicine* 12:7007–7013.
- Wu, Y.T., Chen, L., Tan, Z. Bin, et al., 2018. Luteolin inhibits vascular smooth muscle cell proliferation and migration by inhibiting TGFBR1 signaling, *Frontiers in Pharmacology* 9 (SEP):1–11.
- X, Y., M, C., JH, K., et al., 2019. Hexokinase 2 couples glycolysis with the profibrotic actions of TGF- $\beta$ , *Science Signaling Sci Signal* 12 (612):, available at:<https://doi.org/10.1126/SCISIGNAL.AAX4067>.
- Xavier, G.M., Panousopoulos, L. and Cobourne, M.T., 2013. Scube3 is expressed

in multiple tissues during development but is dispensable for embryonic survival in the mouse., *PloS One* United States8 (1):e55274.

Xavier, S., Vasko, R., Matsumoto, K., et al., 2015. Curtailing endothelial TGF- $\beta$  signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD, *Journal of the American Society of Nephrology : JASN* J Am Soc Nephrol26 (4):817–829.

Xu, P., Luo, A., Xiong, C., Ren, H., Yan, L. and Luo, Q., 2022. SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGF $\beta$ /PI3K/AKT/GSK3 $\beta$  pathway, *Cancer Cell International* 22 (1):1.

Zamzam, M.A., Abd El-Aziz, A.A., El Wahsh, R.A., Sonbol, A.A. and Abu El Nour, S.M., 2016. Role of interleukin-6 in diagnosis of pleural effusion, *Egyptian Journal of Chest Diseases and Tuberculosis* No longer published by Elsevier65 (1):173–177.

Zhao, H., Zhu, W., Jia, L., et al., 2016. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy., *The British Journal of Radiology* England89 (1058):20150665.

